Repeated Dosing Study to Assess Safety and Tolerability in CKD-3 Patients on Stable ACE-I Treatment

Exclusion Criteria

• •Women of child bearing potential.
• •Uncontrolled clinically relevant cardiovascular, pulmonary, gastro-intestinal, metabolic, hematological, neurological, psychiatric, systemic, ocular, gynecologic (if female) or infectious disease, or signs of acute illness
• •Active hepatitis, hepatic insufficiency
• •Acute renal failure
• •Patients requiring dialysis during the study
• •Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician.
• •Any history of orthostatic dysregulation (including but not limited to neurocardiogenic syncope, postural orthostatic tachycardia syndrome)
• •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.